DHF
MCID: DNG002
MIFTS: 65

Dengue Hemorrhagic Fever (DHF)

Categories: Blood diseases, Infectious diseases

Aliases & Classifications for Dengue Hemorrhagic Fever

MalaCards integrated aliases for Dengue Hemorrhagic Fever:

Name: Dengue Hemorrhagic Fever 38 12 55 3 15
Severe Dengue 44 73
Dhf 12 3
Dengue Haemorrhagic Fever 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12206
ICD10 33 A91
MeSH 44 D019595
NCIt 50 C34683
SNOMED-CT 68 20927009
UMLS 73 C0019100

Summaries for Dengue Hemorrhagic Fever

CDC : 3 With more than one-third of the world’s population living in areas at risk for infection, dengue virus is a leading cause of illness and death in the tropics and subtropics. As many as 400 million people are infected yearly. Dengue is caused by any one of four related viruses transmitted by mosquitoes. There are not yet any vaccines to prevent infection with dengue virus and the most effective protective measures are those that avoid mosquito bites. When infected, early recognition and prompt supportive treatment can substantially lower the risk of medical complications and death.

MalaCards based summary : Dengue Hemorrhagic Fever, also known as severe dengue, is related to hemorrhagic fever and dengue shock syndrome, and has symptoms including thrombocytopenia, high fever and hemorrhagic lesions of the skin. An important gene associated with Dengue Hemorrhagic Fever is CD209 (CD209 Molecule), and among its related pathways/superpathways are Innate Immune System and TGF-Beta Pathway. The drugs Ketotifen and Histamine have been mentioned in the context of this disorder. Affiliated tissues include skin, endothelial and liver, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A dengue disease that occurs when a person experiences a second infection with a heterologous Dengue virus serotype, which is transmitted by Aedes mosquito bite. The infection has symptom hemorrhagic lesions of the skin, has symptom thrombocytopenia, has symptom reduction in the fluid part of the blood, and has symptom high fever.

Related Diseases for Dengue Hemorrhagic Fever

Diseases related to Dengue Hemorrhagic Fever via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 381)
# Related Disease Score Top Affiliating Genes
1 hemorrhagic fever 31.3 ALB CD209 F2 F3 HLA-DRB1 IFNG
2 dengue shock syndrome 30.7 CMA1 HLA-A HLA-DRB1 IL6 TNF
3 acute pancreatitis 30.5 CXCL8 IL10 IL6
4 compartment syndrome 30.4 ALB F2 TNF
5 hemophagocytic lymphohistiocytosis 30.4 CXCL8 IFNG IL10 TNF
6 myocarditis 30.4 HLA-B IL6 TNF
7 acute disseminated encephalomyelitis 30.1 HLA-B HLA-DRB1 IL10
8 acute respiratory distress syndrome 30.0 CXCL8 IL6 TNF
9 japanese encephalitis 29.9 CD209 STAT1 TLR3 TNF
10 purpura 29.9 F2 F3 IL6 TNF
11 hepatitis a 29.9 ALB F2 IFNG IL10 TNF
12 aspergillosis 29.9 CD209 IFNG IL10 TNF
13 pneumonia 29.8 CXCL8 IL10 IL6 TNF
14 kawasaki disease 29.8 ALB FCGR2A IL10 IL6 TNF
15 filariasis 29.8 ALB IFNG IL10 IL6 TNF
16 typhoid fever 29.8 ALB F2 IFNG IL6 TNF
17 fasciitis 29.7 CXCL8 IL6 TNF
18 peritonitis 29.5 ALB CXCL8 F2 IL10 IL6 TNF
19 acquired immunodeficiency syndrome 29.5 ALB HLA-B IFNG IL10 IL6 TNF
20 respiratory failure 29.3 ALB CXCL8 F3 TNF
21 viral infectious disease 29.3 CD209 CXCL8 IFNG IL10 IL6 STAT1
22 diabetes mellitus 28.9 ALB HLA-A HLA-B HLA-DRB1 IFNG IL6
23 malaria 28.8 ALB CXCL8 F3 FCGR2A HLA-A HLA-B
24 dengue disease 12.3
25 dengue virus 11.7
26 thrombocytopenia 10.5
27 diastolic heart failure 10.4
28 endomyocardial fibrosis 10.4 IL10 TNF
29 acute liver failure 10.4
30 pancreatitis 10.4
31 multifocal choroiditis 10.3 IL10 TNF
32 punctate inner choroidopathy 10.3 IL10 TNF
33 tropical endomyocardial fibrosis 10.3 IL10 TNF
34 juvenile myasthenia gravis 10.3 HLA-DRB1 IL10
35 leech infestation 10.3 F2 F3
36 cephalosporin allergy 10.3 IFNG IL10
37 hyperlucent lung 10.3 IFNG IL10
38 prothrombin deficiency 10.3 F2 F3
39 sporotrichosis 10.3 IFNG IL10
40 cerebral falx meningioma 10.3 F2 F3
41 intestinal impaction 10.3 F2 F3
42 autoimmune myocarditis 10.3 IFNG TNF
43 encephalopathy 10.3
44 staphylococcal toxic shock syndrome 10.3 IFNG TNF
45 cerebral sinovenous thrombosis 10.3 F2 F3
46 antipyrine metabolism 10.3 ALB F2
47 heparin-induced thrombocytopenia 10.3 F3 FCGR2A
48 epstein-barr virus hepatitis 10.3 ALB F2
49 abdominal tuberculosis 10.3 ALB F2
50 non-a-e hepatitis 10.3 ALB F2

Graphical network of the top 20 diseases related to Dengue Hemorrhagic Fever:



Diseases related to Dengue Hemorrhagic Fever

Symptoms & Phenotypes for Dengue Hemorrhagic Fever

Symptoms:

12
  • thrombocytopenia
  • high fever
  • hemorrhagic lesions of the skin
  • reduction in the fluid part of the blood

MGI Mouse Phenotypes related to Dengue Hemorrhagic Fever:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.06 CMA1 F2 F3 FCGR2A IFNG IL10
2 immune system MP:0005387 10 CMA1 F2 F3 FCGR2A IFNG IL10
3 digestive/alimentary MP:0005381 9.91 ALB F2 IFNG IL10 IL6 STAT1
4 muscle MP:0005369 9.76 ALB F3 IFNG IL10 IL6 STAT1
5 neoplasm MP:0002006 9.56 ALB F3 IFNG IL10 IL6 STAT1
6 respiratory system MP:0005388 9.17 F2 F3 IFNG IL10 IL6 TLR3

Drugs & Therapeutics for Dengue Hemorrhagic Fever

Drugs for Dengue Hemorrhagic Fever (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 40)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketotifen Approved Phase 4 34580-14-8, 34580-13-7 3827
2
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
3 Anti-Allergic Agents Phase 4
4
Histamine Phosphate Phase 4 51-74-1 65513
5 Antipruritics Phase 4
6 Histamine H1 Antagonists Phase 4
7 Neurotransmitter Agents Phase 4
8 Dermatologic Agents Phase 4
9 Histamine Antagonists Phase 4
10
Ivermectin Approved, Investigational, Vet_approved Phase 2, Phase 3 70288-86-7 6474909
11 Pharmaceutical Solutions Phase 3,Phase 2
12 Anti-Infective Agents Phase 2, Phase 3
13 Antiparasitic Agents Phase 2, Phase 3
14 Immunologic Factors Phase 3,Phase 2,Phase 1
15 Vaccines Phase 3,Phase 2,Phase 1,Not Applicable
16 Heptavalent Pneumococcal Conjugate Vaccine Phase 3,Phase 2
17
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
18
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
19
Ribavirin Approved Phase 2 36791-04-5 37542
20
Neomycin Approved, Vet_approved Phase 1, Phase 2 1404-04-2 8378
21 Antimetabolites Phase 2
22 Hydrocortisone 17-butyrate 21-propionate Phase 2
23 Cortisol succinate Phase 2
24 Antiviral Agents Phase 2
25 Hemostatics Phase 2
26 Coagulants Phase 2
27 Antibodies Phase 1, Phase 2,Phase 2
28 Immunoglobulins Phase 1, Phase 2,Phase 2
29
Aluminum sulfate Approved Phase 1 10043-01-3
30
Aluminum hydroxide Approved, Investigational Phase 1 21645-51-2
31 Anti-Ulcer Agents Phase 1
32 Adjuvants, Immunologic Phase 1
33 Antacids Phase 1
34 Gastrointestinal Agents Phase 1
35
Permethrin Approved, Investigational Not Applicable 52645-53-1 40326
36 gamma-Globulins Not Applicable
37 Immunoglobulins, Intravenous Not Applicable
38 Rho(D) Immune Globulin Not Applicable
39 Mitogens
40 Endothelial Growth Factors

Interventional clinical trials:

(show top 50) (show all 112)
# Name Status NCT ID Phase Drugs
1 Ketotifen as a Treatment for Vascular Leakage During Dengue Fever Unknown status NCT02673840 Phase 4 Ketotifen;Placebo
2 Effect of Hypertonic Sodium Lactate on sVCAM-1 Level as Surrogate Marker of Endothelial Capillary Leakage in Pediatric Dengue Shock Syndrome Patients (DSS) Unknown status NCT00966628 Phase 3 Hypertonic sodium lactate;Ringer's lactate
3 Efficacy and Safety of Ivermectin Against Dengue Infection Unknown status NCT02045069 Phase 2, Phase 3 2 days Ivermectin;3 days Ivermectin;Placebo
4 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America Unknown status NCT01374516 Phase 3
5 Study of a Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 11 Years in Malaysia Completed NCT01254422 Phase 3
6 Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia Completed NCT01134263 Phase 3
7 Study of a Novel Tetravalent Dengue Vaccine in Healthy Children Aged 2 to 14 Years in Asia Completed NCT01373281 Phase 3
8 Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers Completed NCT01411241 Phase 3
9 Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue Completed NCT03423173 Phase 3
10 Study of Yellow Fever Vaccine Administered With Tetravalent Dengue Vaccine in Healthy Toddlers Completed NCT01436396 Phase 3
11 Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects Active, not recruiting NCT02992418 Phase 3
12 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil® Active, not recruiting NCT02993757 Phase 3
13 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Cervarix® Active, not recruiting NCT02979535 Phase 3
14 Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Active, not recruiting NCT02747927 Phase 3 TDV Placebo
15 Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) at the End of Shelf Life in Healthy Adults Not yet recruiting NCT03771963 Phase 3
16 Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms Unknown status NCT01973855 Phase 2 Western Medicine;TCM and Western Medicine
17 Activated Recombinant Human Factor VII in Patients With Dengue Haemorrhagic Fever Completed NCT01601613 Phase 2 activated recombinant human factor VII;placebo
18 Celgosivir as a Treatment Against Dengue Completed NCT01619969 Phase 1, Phase 2 celgosivir;placebo
19 A Study of Dengue Vaccine in Healthy Toddlers Aged 12 to 15 Months in the Philippines Completed NCT01064141 Phase 2
20 Study of CYD Dengue Vaccine in Healthy Children and Adolescents in South America Completed NCT01187433 Phase 2
21 Immunogenicity and Safety of Three Formulations of Dengue Vaccines in Healthy Adults Aged 18 to 45 Years in the US Completed NCT00617344 Phase 2
22 Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India Completed NCT01550289 Phase 2
23 Immunologic Mechanisms of Immune Interference and/or Cross-Neutralizing Immunity After CYD Tetravalent Dengue Vaccine Completed NCT01943825 Phase 2
24 Safety and Immunogenicity of Formulations of Dengue Vaccines in Healthy Flavivirus-Naïve Adults Completed NCT00740155 Phase 2
25 Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects Completed NCT00730288 Phase 2
26 Study of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Subjects in Singapore Completed NCT00880893 Phase 2
27 Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America Completed NCT00993447 Phase 2
28 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Subjects Completed NCT00875524 Phase 2
29 Efficacy and Safety of Dengue Vaccine in Healthy Children Completed NCT00842530 Phase 2
30 Study of ChimeriVax™ Tetravalent Dengue Vaccine in Healthy Peruvian Children Aged 2 to 11 Years Completed NCT00788151 Phase 2
31 Immune Response to Different Schedules of a Tetravalent Dengue Vaccine Given With or Without Yellow Fever Vaccine Completed NCT01488890 Phase 2
32 A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children Completed NCT00468858 Phase 2
33 Safety and Immunogenicity With Two Different Serotype 2 Potencies of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Adults in Singapore Completed NCT02425098 Phase 2
34 Safety and Immunogenicity of Three Formulations of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) Completed NCT02193087 Phase 2 TDV Liquid Formulation 1;TDV Liquid Formulation 2;TDV IDT Lyophilized;Placebo
35 A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children Completed NCT00384670 Phase 1, Phase 2
36 A Phase I/II Trial of Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naive Infants Completed NCT00322049 Phase 1, Phase 2
37 Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years Completed NCT01511250 Phase 2
38 Pharmacokinetics and Pharmacodynamics of Ivermectin in Pediatric Dengue Patients Recruiting NCT03432442 Phase 2 Ivermectin
39 Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults Recruiting NCT03746015 Phase 2
40 Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule Active, not recruiting NCT02824198 Phase 2
41 Immunogenicity and Safety of Different Vaccination Schedules of Tetravalent Dengue Vaccine in Healthy Subjects 9 to 50 Years of Age Active, not recruiting NCT02628444 Phase 2
42 Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule Active, not recruiting NCT02623725 Phase 2
43 Safety and Immunogenicity of Different Schedules of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) in Healthy Participants Active, not recruiting NCT02302066 Phase 2 TDV Placebo
44 VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents Active, not recruiting NCT03110770 Phase 2
45 Celgosivir or Modipafant as Treatment for Adult Participants With Uncomplicated Dengue Fever in Singapore Not yet recruiting NCT02569827 Phase 1, Phase 2 Celgosivir;Modipafant 50mg;Placebo;Modipafant 100mg
46 Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults Not yet recruiting NCT02741128 Phase 2
47 Safety of and Immune Response to Two Different Dengue Virus Vaccines in Individuals Previously Immunized Against Dengue Virus Completed NCT00458120 Phase 1
48 A Study of Balapiravir in Patients With Dengue Virus Infection Completed NCT01096576 Phase 1 balapiravir [RO4588161];placebo
49 Safety and Immunogenicity Study to Assess TDV, a Live Attenuated Tetravalent Vaccine for Prevention of Dengue Fever Completed NCT01224639 Phase 1
50 Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus Completed NCT00919178 Phase 1

Search NIH Clinical Center for Dengue Hemorrhagic Fever

Cochrane evidence based reviews: severe dengue

Genetic Tests for Dengue Hemorrhagic Fever

Anatomical Context for Dengue Hemorrhagic Fever

MalaCards organs/tissues related to Dengue Hemorrhagic Fever:

41
Skin, Endothelial, Liver, Kidney, Pituitary, Monocytes, Heart

Publications for Dengue Hemorrhagic Fever

Articles related to Dengue Hemorrhagic Fever:

(show top 50) (show all 687)
# Title Authors Year
1
Platelet Count, D-Dimer, Component Therapy and Dengue Hemorrhagic Fever. ( 29622891 )
2018
2
Climate variability and dengue hemorrhagic fever in Southeast Sulawesi Province, Indonesia. ( 29549613 )
2018
3
Dengue Hemorrhagic Fever Virus in Saudi Arabia: A Review. ( 29319426 )
2018
4
Prospective forecasts of annual dengue hemorrhagic fever incidence in Thailand, 2010-2014. ( 29463757 )
2018
5
The Autoimmune Mechanism in Dengue Hemorrhagic Fever. ( 29686179 )
2018
6
Culture-positive unilateral panophthalmitis in a serology-positive case of dengue hemorrhagic fever. ( 29941760 )
2018
7
Concurrent methicillin-resistant Staphylococcus aureus septicemia and pyomyositis in a patient with dengue hemorrhagic fever: a case report. ( 29486726 )
2018
8
Lessons learnt from managing a case of dengue hemorrhagic fever complicated with acute liver failure and acute kidney injury: a case report. ( 30089506 )
2018
9
Climate Variability and Dengue Hemorrhagic Fever in Hanoi, Viet Nam, During 2008 to 2015. ( 30045631 )
2018
10
Platelet Transfusion Related Panophthalmitis and Endophthalmitis in Patients with Dengue Hemorrhagic Fever. ( 30062992 )
2018
11
Is Total Serum Nitrite and Nitrate (NOx) Level in Dengue Patients a Potential Prognostic Marker of Dengue Hemorrhagic Fever? ( 30069272 )
2018
12
Early Detection of Plasma Leakage in Dengue Hemorrhagic Fever. ( 30333266 )
2018
13
Comment on: Culture-positive unilateral panophthalmitis in a serology-2 positive case of dengue hemorrhagic fever. ( 30355903 )
2018
14
Response to comment on: Culture-positive unilateral panophthalmitis in a serology-2 positive case of dengue hemorrhagic fever. ( 30355904 )
2018
15
Management of Diabetic Ketoacidosis with Dengue Hemorrhagic Fever. ( 30473969 )
2018
16
Clinical profile and predictors of Severe Dengue disease: A study from South India. ( 30510647 )
2018
17
Diabetic patients suffering dengue are at risk for development of dengue shock syndrome/severe dengue: Emphasizing the impacts of co-existing comorbidity(ies) and glycemic control on dengue severity. ( 30146413 )
2018
18
Elimination of Falciparum Malaria and Emergence of Severe Dengue: An Independent or Interdependent Phenomenon? ( 29899735 )
2018
19
Risk of severe dengue is higher in patients with sickle cell disease: a scoping review. ( 30476342 )
2018
20
Validation of Serum Aminotransferases Levels to Define Severe Dengue Fever in Children. ( 30345242 )
2018
21
Fatal Intracranial Hemorrhage in a Patient with Severe Dengue Fever. ( 29492121 )
2018
22
Analyses of clinical and laboratory characteristics of dengue adults at their hospital presentations based on the World Health Organization clinical-phase framework: Emphasizing risk of severe dengue in the elderly. ( 28734676 )
2018
23
Clinical and Laboratory Factors Associated with Severe Dengue: A Case-Control Study of Hospitalized Children. ( 29059411 )
2018
24
A novel predictor of severe dengue: The aspartate aminotransferase/platelet count ratio index (APRI). ( 29315684 )
2018
25
Development of a Prognostic Prediction Model to Determine Severe Dengue in Children. ( 29344875 )
2018
26
Serum metabolome changes in adult patients with severe dengue in the critical and recovery phases of dengue infection. ( 29364889 )
2018
27
Spontaneous calf haematoma in severe dengue. ( 29374645 )
2018
28
Metformin Use and Severe Dengue in Diabetic Adults. ( 29463812 )
2018
29
Severe Dengue: Developing a Universally Applicable Simple Prediction Model. ( 29637462 )
2018
30
Targeted Interventions in Critically Ill Children with Severe Dengue. ( 29657372 )
2018
31
Definitions for warning signs and signs of severe dengue according to the WHO 2009 classification: Systematic review of literature. ( 29691914 )
2018
32
Genome-Wide Analysis to Identify HLA Factors Potentially Associated With Severe Dengue. ( 29692780 )
2018
33
Prediction of mortality in severe dengue cases. ( 29783955 )
2018
34
Endogenous gene selection for relative quantification PCR and IL6 transcript levels in the PBMC's of severe and non-severe dengue cases. ( 30071880 )
2018
35
The Sensitivity, Specificity and Accuracy of Warning Signs in Predicting Severe Dengue, the Severe Dengue Prevalence and Its Associated Factors. ( 30223572 )
2018
36
The predictive and diagnostic accuracy of vascular endothelial growth factor and pentraxin-3 in severe dengue. ( 30246621 )
2018
37
Predictive and diagnostic test accuracy of ultrasonography in differentiating severe dengue from nonsevere dengue. ( 30280705 )
2018
38
Association of tumour necrosis factor-α (TNF-α) gene polymorphisms (-308 G>A and -238 G>A) and the risk of severe dengue: A meta-analysis and trial sequential analysis. ( 30300401 )
2018
39
Virus-inclusive single-cell RNA sequencing reveals the molecular signature of progression to severe dengue. ( 30530648 )
2018
40
Dengue hemorrhagic fever complicated with transient diabetic ketoacidosis: a case report. ( 29078811 )
2017
41
Vitamin D serostatus and dengue fever progression to dengue hemorrhagic fever/dengue shock syndrome. ( 28903788 )
2017
42
Association of Single-Nucleotide Polymorphisms in Immune-Related Genes with Development of Dengue Hemorrhagic Fever in a Mexican Population. ( 29130827 )
2017
43
Dengue Hemorrhagic Fever in the Northwest of Mexico: A Two-Decade Analysis. ( 28613285 )
2017
44
Spontaneous rectus sheath hematomas in dengue hemorrhagic fever: A case report. ( 28856103 )
2017
45
A pediatric case of imported dengue hemorrhagic fever in Japan. ( 29264075 )
2017
46
Serum cytokine/chemokine profiles in patients with dengue fever (DF) and dengue hemorrhagic fever (FHD) by using protein array. ( 28242509 )
2017
47
Differences in Mortality and Clinical Manifestations of Dengue Hemorrhagic Fever in Taiwan in Different Years: A Comparison for Cases in 2014 and 2015 Epidemics. ( 28722609 )
2017
48
A Correlation of the Platelet Count with D-Dimer Levels as an Indicator for Component Therapy in Children with Dengue Hemorrhagic Fever. ( 28596655 )
2017
49
Dengue Hemorrhagic Fever: A State-of-the-Art Review Focused in Pulmonary Involvement. ( 28612239 )
2017
50
Chymase Level Is a Predictive Biomarker of Dengue Hemorrhagic Fever in Pediatric and Adult Patients. ( 28968807 )
2017

Variations for Dengue Hemorrhagic Fever

Expression for Dengue Hemorrhagic Fever

LifeMap Discovery
Genes differentially expressed in tissues of Dengue Hemorrhagic Fever patients vs. healthy controls: 35 (show top 50) (show all 120)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CD38 CD38 molecule Blood + 4.80 0.000
2 IFI27 interferon, alpha-inducible protein 27 Blood + 4.71 0.000
3 RRM2 ribonucleotide reductase M2 Blood + 4.63 0.000
4 IGHM immunoglobulin heavy constant mu Blood + 4.61 0.000
5 BIRC5 baculoviral IAP repeat containing 5 Blood + 4.47 0.000
6 CAV1 caveolin 1, caveolae protein, 22kDa Blood + 4.41 0.000
7 DLGAP5 discs, large (Drosophila) homolog-associated protein 5 Blood + 4.31 0.000
8 XIST X inactive specific transcript (non-protein coding) Blood - 4.31 0.023
9 CEP55 centrosomal protein 55kDa Blood + 4.28 0.000
10 BUB1 BUB1 mitotic checkpoint serine/threonine kinase Blood + 4.21 0.000
11 SHCBP1 SHC SH2-domain binding protein 1 Blood + 4.13 0.000
12 PBK PDZ binding kinase Blood + 4.13 0.000
13 IGKV3-20 immunoglobulin kappa variable 3-20 Blood + 4.13 0.000
14 TYMS thymidylate synthetase Blood + 4.07 0.000
15 CDCA2 cell division cycle associated 2 Blood + 4.06 0.000
16 MKI67 marker of proliferation Ki-67 Blood + 4.00 0.000
17 CYAT1 immunoglobulin lambda light chain-like Blood + 3.98 0.000
18 MCM10 minichromosome maintenance 10 replication initiation factor Blood + 3.98 0.000
19 NOV nephroblastoma overexpressed Blood - 3.97 0.000
20 ZWINT ZW10 interacting kinetochore protein Blood + 3.96 0.000
21 CDK1 cyclin-dependent kinase 1 Blood + 3.92 0.000
22 HMMR hyaluronan-mediated motility receptor (RHAMM) Blood + 3.90 0.000
23 SDC1 syndecan 1 Blood + 3.89 0.000
24 SPC25 SPC25, NDC80 kinetochore complex component Blood + 3.84 0.000
25 NCAPG non-SMC condensin I complex, subunit G Blood + 3.84 0.000
26 TK1 thymidine kinase 1, soluble Blood + 3.82 0.000
27 CDC20 cell division cycle 20 Blood + 3.80 0.000
28 TNFRSF17 tumor necrosis factor receptor superfamily, member 17 Blood + 3.80 0.000
29 DTL denticleless E3 ubiquitin protein ligase homolog (Drosophila) Blood + 3.80 0.000
30 TOP2A topoisomerase (DNA) II alpha Blood + 3.80 0.000
31 PI3 peptidase inhibitor 3, skin-derived Blood - 3.76 0.000
32 GLDC glycine dehydrogenase (decarboxylating) Blood + 3.75 0.000
33 IGLJ3 immunoglobulin lambda joining 3 Blood + 3.75 0.000
34 SESN3 sestrin 3 Blood - 3.75 0.000
35 KIF2C kinesin family member 2C Blood + 3.74 0.000
36 CDT1 chromatin licensing and DNA replication factor 1 Blood + 3.72 0.000
37 CDKN3 cyclin-dependent kinase inhibitor 3 Blood + 3.71 0.000
38 KIAA0101 KIAA0101 Blood + 3.71 0.000
39 EIF1AY eukaryotic translation initiation factor 1A, Y-linked Blood + 3.71 0.034
40 CNTNAP3 contactin associated protein-like 3 Blood - 3.70 0.000
41 CENPA centromere protein A Blood + 3.69 0.000
42 TTK TTK protein kinase Blood + 3.67 0.000
43 ASPM abnormal spindle microtubule assembly Blood + 3.66 0.000
44 KIF11 kinesin family member 11 Blood + 3.64 0.000
45 IGL immunoglobulin lambda locus Blood + 3.64 0.000
46 CCNB2 cyclin B2 Blood + 3.61 0.000
47 BUB1B BUB1 mitotic checkpoint serine/threonine kinase B Blood + 3.60 0.000
48 CDC6 cell division cycle 6 Blood + 3.60 0.000
49 SLC2A5 solute carrier family 2 (facilitated glucose/fructose transporter), member 5 Blood + 3.60 0.000
50 DUSP5 dual specificity phosphatase 5 Blood + 3.60 0.000
Search GEO for disease gene expression data for Dengue Hemorrhagic Fever.

Pathways for Dengue Hemorrhagic Fever

Pathways related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 CD209 CXCL8 FCGR2A HLA-A HLA-B HLA-DRB1
2
Show member pathways
13.57 CXCL8 F2 IFNG IL10 IL6 STAT1
3
Show member pathways
13.43 CXCL8 IL10 IL6 STAT1 STAT2 TLR3
4
Show member pathways
13.33 CXCL8 HLA-A HLA-B HLA-DRB1 IFNG IL10
5
Show member pathways
13.22 HLA-DRB1 IFNG STAT1 STAT2 TLR3 TNF
6
Show member pathways
13.1 CXCL8 HLA-A HLA-B IL6 STAT1 STAT2
7
Show member pathways
13.08 HLA-A HLA-B IL6 STAT1 STAT2 TLR3
8
Show member pathways
13.03 CXCL8 IFNG IL10 IL6 STAT1 STAT2
9 12.87 CXCL8 IFNG IL6 STAT1 STAT2
10
Show member pathways
12.8 CXCL8 IFNG IL6 TLR3 TNF
11
Show member pathways
12.8 CXCL8 HLA-A HLA-B HLA-DRB1 IFNG IL10
12
Show member pathways
12.68 HLA-DRB1 IFNG IL10 IL6 STAT1 TNF
13
Show member pathways
12.67 F2 IFNG IL10 IL6 STAT1 TNF
14 12.65 IFNG IL10 STAT1 STAT2 TLR3 TNF
15
Show member pathways
12.62 HLA-A HLA-B HLA-DRB1 IFNG STAT1 STAT2
16
Show member pathways
12.53 HLA-A HLA-B IFNG TNF
17 12.51 HLA-A HLA-B HLA-DRB1 IL6 TNF
18
Show member pathways
12.47 IFNG IL10 IL6 STAT1 STAT2
19
Show member pathways
12.46 IFNG IL10 IL6 TNF
20
Show member pathways
12.43 ALB F2 IFNG IL6 TNF
21
Show member pathways
12.38 CXCL8 IFNG IL6 TNF
22
Show member pathways
12.37 CXCL8 IFNG IL6 STAT1 TLR3 TNF
23
Show member pathways
12.35 IFNG IL6 STAT1 STAT2
24
Show member pathways
12.33 CXCL8 F3 IL6 STAT1 TNF
25
Show member pathways
12.31 CXCL8 IL6 TLR3 TNF
26
Show member pathways
12.31 IFNG STAT1 STAT2 TLR3 TNF
27
Show member pathways
12.29 CXCL8 IFNG IL6 STAT1 TNF
28
Show member pathways
12.29 FCGR2A HLA-DRB1 IFNG IL10 STAT1 TNF
29 12.28 IFNG IL6 STAT1 TLR3 TNF
30 12.23 CXCL8 IL10 IL6 TNF
31 12.23 CD209 FCGR2A HLA-A HLA-B HLA-DRB1
32 12.22 CXCL8 HLA-A HLA-B IL6
33 12.22 HLA-A HLA-B HLA-DRB1 IL6 STAT1 STAT2
34
Show member pathways
12.21 CD209 IL10 IL6 STAT1 STAT2 TNF
35
Show member pathways
12.18 CXCL8 IFNG IL10 IL6 STAT1 STAT2
36 12.15 CXCL8 STAT1 STAT2 TLR3 TNF
37 12.14 FCGR2A IFNG STAT1 STAT2 TNF
38 12.13 IL6 STAT1 STAT2 TNF
39
Show member pathways
12.13 F2 FCGR2A IFNG IL6 TNF
40 12.09 CXCL8 FCGR2A IFNG IL6 TNF
41
Show member pathways
12.06 HLA-A HLA-DRB1 IFNG STAT1
42 12.06 CXCL8 IL10 IL6 STAT1 TNF
43
Show member pathways
12.05 CD209 CXCL8 HLA-A HLA-B HLA-DRB1 IFNG
44
Show member pathways
12.02 CXCL8 HLA-A HLA-B IFNG IL10 IL6
45 11.97 IFNG IL10 IL6 STAT1 STAT2
46 11.97 CD209 FCGR2A IFNG IL10 IL6 TNF
47 11.96 CXCL8 IFNG IL6
48 11.96 CXCL8 F3 IL6 STAT1 TNF
49 11.94 CXCL8 IFNG IL10 IL6 TNF
50 11.92 HLA-DRB1 IL6 TNF

GO Terms for Dengue Hemorrhagic Fever

Cellular components related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.85 ALB CD209 CMA1 CXCL8 F2 F3
2 ER to Golgi transport vesicle membrane GO:0012507 9.5 HLA-A HLA-B HLA-DRB1
3 cell surface GO:0009986 9.5 CD209 F3 HLA-A HLA-B HLA-DRB1 TLR3
4 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.43 HLA-A HLA-B HLA-DRB1
5 MHC class I protein complex GO:0042612 9.37 HLA-A HLA-B
6 extracellular space GO:0005615 9.32 ALB CMA1 CXCL8 F2 F3 IFNG

Biological processes related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.93 CXCL8 IL10 IL6 TLR3 TNF
2 regulation of signaling receptor activity GO:0010469 9.88 CXCL8 F2 IFNG IL10 IL6 TNF
3 cellular response to lipopolysaccharide GO:0071222 9.85 CXCL8 IL10 IL6 TNF
4 positive regulation of angiogenesis GO:0045766 9.81 CMA1 CXCL8 F3 TLR3
5 response to glucocorticoid GO:0051384 9.8 IL10 IL6 TNF
6 positive regulation of interleukin-6 production GO:0032755 9.79 IL6 TLR3 TNF
7 humoral immune response GO:0006959 9.77 IFNG IL6 TNF
8 positive regulation of smooth muscle cell proliferation GO:0048661 9.77 IL6 STAT1 TNF
9 defense response to virus GO:0051607 9.77 IFNG IL6 STAT1 STAT2 TLR3
10 extrinsic apoptotic signaling pathway GO:0097191 9.7 IFNG TLR3 TNF
11 interleukin-6-mediated signaling pathway GO:0070102 9.67 IL6 STAT1
12 negative regulation of growth of symbiont in host GO:0044130 9.66 IL10 TNF
13 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.66 IL10 TNF
14 regulation of interferon-gamma-mediated signaling pathway GO:0060334 9.65 IFNG STAT1
15 response to molecule of bacterial origin GO:0002237 9.65 CXCL8 IL10
16 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.64 HLA-A HLA-B
17 negative regulation of lipid storage GO:0010888 9.64 IL6 TNF
18 endothelial cell apoptotic process GO:0072577 9.63 IL10 TNF
19 positive regulation of chemokine biosynthetic process GO:0045080 9.63 TLR3 TNF
20 antigen processing and presentation of endogenous peptide antigen via MHC class Ib GO:0002476 9.62 HLA-A HLA-B
21 type I interferon signaling pathway GO:0060337 9.62 HLA-A HLA-B STAT1 STAT2
22 positive regulation of chemokine production GO:0032722 9.61 IL6 TLR3 TNF
23 necroptotic signaling pathway GO:0097527 9.58 TLR3 TNF
24 negative regulation of cytokine secretion involved in immune response GO:0002740 9.58 IL10 TNF
25 positive regulation of neuroinflammatory response GO:0150078 9.57 IL6 TNF
26 protection from natural killer cell mediated cytotoxicity GO:0042270 9.56 HLA-A HLA-B
27 antigen processing and presentation GO:0019882 9.56 CD209 HLA-A HLA-B HLA-DRB1
28 immune response GO:0006955 9.56 CXCL8 HLA-A HLA-B HLA-DRB1 IFNG IL10
29 interferon-gamma-mediated signaling pathway GO:0060333 9.55 HLA-A HLA-B HLA-DRB1 IFNG STAT1
30 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.49 IFNG TNF
31 receptor biosynthetic process GO:0032800 9.48 IL10 TNF
32 positive regulation of vitamin D biosynthetic process GO:0060557 9.46 IFNG TNF
33 cytokine-mediated signaling pathway GO:0019221 9.17 CXCL8 F3 IL10 IL6 STAT1 STAT2
34 immune system process GO:0002376 10.05 CD209 HLA-A HLA-B HLA-DRB1 TLR3
35 viral process GO:0016032 10 CD209 HLA-B HLA-DRB1 STAT1 STAT2

Molecular functions related to Dengue Hemorrhagic Fever according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.35 CXCL8 IFNG IL10 IL6 TNF
2 peptide antigen binding GO:0042605 8.92 CD209 HLA-A HLA-B HLA-DRB1
3 protein binding GO:0005515 10.03 ALB CD209 CXCL8 F2 F3 FCGR2A

Sources for Dengue Hemorrhagic Fever

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....